Shanda Blackmon, Professor Of Surgery in the Division of Thoracic Surgery at Baylor College of Medicine and Director of the Lung Institute at Baylor Medicine, shared on X:
“First trial of CAR-T cell cancer treatment for solid tumor response:
Satricabtagene autoleucel (satri-cel)/CT041 demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit in patients with previously treated, advanced G/GEJC.
Globally, this is the first ever randomized controlled trial of a CAR-T cell therapy in
solid tumors to achieve superiority.Satri-cel showed a manageable safety profile consistent with previous phase I results. This trial expanded the percentage of CLDN18.2 positive patients with G/GEJC.
These results support satri-cel as a new treatment option for advanced G/GEJC.”
